Search Results - "Mastrangelo, Michael J."

Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy by Sato, Takami, Terai, Mizue, Tamura, Yutaka, Alexeev, Vitali, Mastrangelo, Michael J., Selvan, Senthamil R.

“…IL-10 is an immunomodulatory cytokine that is frequently upregulated in various types of cancer. The biological role of IL-10 in cancer is quite complex;…”
Get full text

PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma by Javed, Asad, Arguello, David, Johnston, Curtis, Gatalica, Zoran, Terai, Mizue, Weight, Ryan M, Orloff, Marlana, Mastrangelo, Michael J, Sato, Takami

“…To compare PD-L1 expression between metastatic uveal melanoma (MUM) and metastatic cutaneous melanoma (MCM). A total of 295 MCM and 78 MUM specimens were…”
Get full text

Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization by Ozaki, Shinji, Vuyyuru, Raja, Kageyama, Ken, Terai, Mizue, Ohara, Masahiro, Cheng, Hanyin, Manser, Tim, Mastrangelo, Michael J, Aplin, Andrew E, Sato, Takami

“…Uveal melanoma (UM) is a rare type of melanoma, although it is the most common primary ocular malignant tumor in adults. Nearly one-half the patients with…”
Get full text

Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis by Kageyama, Ken, Ohara, Masahiro, Saito, Kengo, Ozaki, Shinji, Terai, Mizue, Mastrangelo, Michael J, Fortina, Paolo, Aplin, Andrew E, Sato, Takami

“…Metastatic uveal melanoma is a highly fatal disease; most patients die from their hepatic metastasis within 1 year. A major drawback in the development of new…”
Get full text

Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma by Berger, Adam C., MD, FACS, Ollila, David W., MD, FACS, Christopher, Adrienne, BA, Kairys, John C., MD, Mastrangelo, Michael J., MD, Feeney, Kendra, MD, Dabbish, Nooreen, PhD, Leiby, Benjamin, PhD, Frank, Jill A., MS, Stitzenberg, Karyn B., MD, FACS, Meyers, Michael O., MD, FACS

“…Abstract Background Patients with stage II melanoma have significant recurrence risk. Current guidelines are imprecise as to optimal follow-up. We hypothesized…”
Get full text

The Last Chapter by Mastrangelo, Michael J., MD

Get full text

Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte–Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases by Valsecchi, Matias E., MD, MS, Terai, Mizue, PhD, Eschelman, David J., MD, Gonsalves, Carin F., MD, Chervoneva, Inna, PhD, Shields, Jerry A., MD, Shields, Carol L., MD, Yamamoto, Akira, MD, Sullivan, Kevin L., MD, Laudadio, MaryAnn, RN, Berd, David, MD, Mastrangelo, Michael J., MD, Sato, Takami, MD, PhD

“…Abstract Purpose To investigate the effects of immunoembolization with granulocyte–macrophage colony-stimulating factor (GM-CSF) in patients with uveal…”
Get full text

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 by Ascierto, Paolo Antonio, Fox, Bernard, Urba, Walter, Anderson, Ana Carrizosa, Atkins, Michael B, Borden, Ernest C, Brahmer, Julie, Butterfield, Lisa H, Cesano, Alessandra, Chen, Daniel, de Gruijl, Tanja, Dillman, Robert O, Drake, Charles G, Emens, Leisha A, Gajewski, Thomas F, Gulley, James L, Stephen Hodi, F, Hwu, Patrick, Kaufman, David, Kaufman, Howard, Lotze, Michael, McNeel, Douglas G, Margolin, Kim, Marincola, Francesco, Mastrangelo, Michael J, Maus, Marcela V, Parkinson, David R, Romero, Pedro J, Sondel, Paul M, Spranger, Stefani, Sznol, Mario, Weiner, George J, Wiggington, Jon M, Weber, Jeffrey S

“…Tocilizumab also is already FDA approved to manage cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor T cell therapy.4 5 In…”
Get full text

Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor by SATO, Takami, ESCHELMAN, David J, MASTRANGELO, Michael J, SULLIVAN, Kevin L, GONSALVES, Carin F, TERAI, Mizue, CHERVONEVA, Inna, MCCUE, Peter A, SHIELDS, Jerry A, SHIELDS, Carol L, YAMAMOTO, Akira, BERD, David

“…We conducted a phase I study to investigate the feasibility and safety of immunoembolization with granulocyte-macrophage colony-stimulating factor (GM-CSF;…”
Get full text

Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells by Terai, Mizue, Mu, Zhaomei, Eschelman, David J., Gonsalves, Carin F., Kageyama, Ken, Chervoneva, Inna, Orloff, Marlana, Weight, Ryan, Mastrangelo, Michael J., Cristofanilli, Massimo, Sato, Takami

“…CTCs provide prognostic information and their application is under investigation in multiple tumor types. Of the multiple variables inherent in any such…”
Get full text

Interleukin 6 mediates production of interleukin 10 in metastatic melanoma by Terai, Mizue, Eto, Masumi, Young, Garbo D., Berd, David, Mastrangelo, Michael J., Tamura, Yutaka, Harigaya, Kenichi, Sato, Takami

“…We previously reported that substantial amounts of IL-10, an immunomodulatory cytokine, are produced by cell suspensions of fresh human metastatic melanoma…”
Get full text

Immunopharmacologic Analysis of an Autologous, Hapten-Modified Human Melanoma Vaccine by BERD, David, SATO, Takami, MAGUIRE, Henry C, KAIRYS, John, MASTRANGELO, Michael J

“…We have previously reported a clinical trial of a human cancer vaccine consisting of autologous tumor cells modified with the hapten, dinitrophenyl (DNP), in…”
Get full text

Intralesional Therapy for In-transit and Satellite Metastases in Melanoma by Feeney, Kendra J., MD, Mastrangelo, Michael J., MD

“…Intratumoral therapy with bacteria/bacterial products dates to at least the 1890s. Over the decades this has expanded beyond the use of microbes and microbial…”
Get full text

Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls by Valsecchi, Matias E, Orloff, Marlana, Sato, Rino, Chervoneva, Inna, Shields, Carol L, Shields, Jerry A, Mastrangelo, Michael J, Sato, Takami

“…To compare overall survival in high-risk patients with primary uveal melanoma who received adjuvant sunitinib with institutional controls. Retrospective…”
Get full text

Altered drainage patterns in patients with melanoma and previous axillary dissection by Johnson, Caitlyn, Intenzo, Charles, Mastrangelo, Michael J., Feeney, Kendra, Berger, Adam C.

“…The incidence of melanoma is increasing rapidly in the United States. Sentinel lymph node biopsy is an important diagnostic tool in the treatment and staging…”
Get full text

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases by Williams, Noelle L., Wuthrick, Evan J., Kim, Hyun, Palmer, Joshua D., Garg, Shivank, Eldredge-Hindy, Harriet, Daskalakis, Constantine, Feeney, Kendra J., Mastrangelo, Michael J., Kim, Lyndon J., Sato, Takami, Kendra, Kari L., Olencki, Thomas, Liebner, David A., Farrell, Christopher J., Evans, James J., Judy, Kevin D., Andrews, David W., Dicker, Adam P., Werner-Wasik, Maria, Shi, Wenyin

“…We performed a phase 1 study to determine the maximum tolerable dose and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain radiation…”
Get full text

A pilot study of sunitinib malate in patients with metastatic uveal melanoma by Mahipal, Amit, Tijani, Lukman, Chan, Kathryn, Laudadio, MaryAnn, Mastrangelo, Michael J, Sato, Takami

“…The prognosis of patients with metastatic uveal melanoma is poor and there are limited therapeutic options. C-kit is expressed in the majority of patients with…”
Get full text

Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth by Yoshida, Makoto, Selvan, Senthamil, McCue, Peter A., DeAngelis, Tiziana, Baserga, Renato, Fujii, Ami, Rui, Hallgeir, Mastrangelo, Michael J., Sato, Takami

“…Summary We investigated the importance of the insulin‐like growth factor‐1 receptor (IGF‐1R) in hepatic metastases of uveal melanoma. The expression pattern of…”
Get full text

High-Dose Immunoembolization: Survival Benefit in Patients with Hepatic Metastases from Uveal Melanoma1 by YAMAMOTO, Akira, CHERVONEVA, Inna, SATO, Takami, SULLIVAN, Kevin L, ESCHELMAN, David J, GONSALVES, Carin F, MASTRANGELO, Michael J, BERD, David, SHIELDS, Jerry A, SHIELDS, Carol L, TERAI, Mizue

“…Purpose: To retrospectively evaluate prognostic factors for survival in patients with uveal melanoma who received chemoembolization (CE) with 1,3-bis…”
Get full text

An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis by Seedor, Rino S, Eschelman, David J, Gonsalves, Carin F, Adamo, Robert D, Orloff, Marlana, Amjad, Anjum, Sharpe-Mills, Erin, Chervoneva, Inna, Shields, Carol L, Shields, Jerry A, Mastrangelo, Michael J, Sato, Takami

“…There is no FDA-approved treatment for metastatic uveal melanoma (UM) and overall outcomes are generally poor for those who develop liver metastasis. We…”
Get full text